Dr. Li Discusses Low-Grade NMIBC Progression Risks and the Innovative Role of AI in Pathology Assessment

In a recent discussion, Dr. Roger Li, a genitourinary oncologist at Moffitt Cancer Center, addressed the progression risk in patients with low-grade non–muscle-invasive bladder cancer (NMIBC). He highlighted that true progression to muscle-invasive or metastatic disease is rare, affecting fewer than 5% of patients. However, approximately 10% to 20% may progress to high-grade disease, which has significant management implications. The variability in grading due to subjective interpretation by pathologists complicates risk assessment. To enhance risk stratification, Dr. Li emphasized the potential of artificial intelligence (AI) in pathology. AI tools analyzing standard pathology images can identify patterns linked to progression more accurately than human assessment. If validated, AI-driven assessments could support personalized treatment strategies, allowing for intensified monitoring for high-risk patients while minimizing overtreatment for those with low-risk profiles. Ultimately, AI has the potential to revolutionize clinical decision-making in NMIBC, providing objective and accessible risk stratification.

Source link